Summary & Overview
CPT 81403: Advanced Molecular Pathology Procedure, Level 4
CPT code 81403 represents a Level 4 molecular pathology procedure, encompassing complex genetic analyses such as single exon sequencing, multiplex PCR, and mutation scanning for duplication or deletion variants across multiple exons. This code is widely used in clinical laboratories and physician offices to support the diagnosis and management of genetic and chromosomal disorders. Its national relevance stems from the increasing demand for precision medicine and genetic screening, which are integral to modern healthcare.
Major payers including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare provide coverage for services billed under CPT code 81403. The publication offers insights into payer coverage, clinical benchmarks, and policy updates related to this code. Readers will gain an understanding of the clinical context for molecular pathology procedures, typical sites of service, and the importance of advanced genetic testing in patient care. The summary also highlights the role of CPT code 81403 in laboratory medicine and its connection to broader trends in genetic diagnostics.
Key topics covered include payer policies, clinical applications, and the evolving landscape of molecular pathology billing. This information is essential for stakeholders seeking to stay informed about coding practices, reimbursement trends, and the impact of genetic testing on healthcare delivery.
CPT Code Overview
CPT code 81403 is designated for a Level 4 molecular pathology procedure. This code is used for advanced genetic testing, such as the analysis of a single exon by DNA sequence analysis, multiplex PCR involving more than 10 amplicons in multiple reactions, or mutation scanning and detection of duplication/deletion variants across 2 to 5 exons. The service type is Molecular Pathology / Laboratory, and testing is typically performed in a laboratory setting (POS 81) or a physician office (POS 11). These procedures play a critical role in identifying genetic and chromosomal anomalies, supporting clinical decision-making in a variety of medical specialties.
Clinical & Coding Specifications
Clinical Context
A patient presents to a physician's office or laboratory for evaluation of a suspected genetic or metabolic disorder. The clinician orders a molecular pathology procedure to analyze specific genetic regions, such as single exons or multiple amplicons, to detect mutations, duplications, or deletions. The workflow involves specimen collection (e.g., blood or tissue), laboratory processing, and interpretation of results by a pathologist or clinical laboratory specialist. This procedure is commonly performed for patients with abnormal screening results, unexplained metabolic findings, or suspected chromosomal anomalies.
Coding Specifications
-
Modifiers:
- Modifier
26: Used when reporting only the professional component (interpretation of results) of the molecular pathology procedure. - Modifier
TC: Used when reporting only the technical component (performance of the test) of the procedure. - Modifier
59: Used to indicate a distinct procedural service, such as when multiple molecular pathology procedures are performed on the same day.
- Modifier
-
Provider Taxonomies:
| Taxonomy Code | Specialty Name |
|---|---|
207ZP0102X | Pathology - Clinical Pathology/Laboratory Medicine |
207L00000X | Anatomic Pathology |
207Q00000X | Family Medicine |
207R00000X | Internal Medicine |
208D00000X | General Practice |
These specialties represent providers who may order, perform, or interpret molecular pathology procedures.
Related Diagnoses
-
Z13.79: Encounter for other screening for genetic and chromosomal anomalies- Used when the procedure is performed as part of a screening for genetic or chromosomal abnormalities.
-
Q99.9: Chromosomal abnormality, unspecified- Relevant when the patient is suspected to have a chromosomal abnormality that requires molecular analysis.
-
E88.9: Metabolic disorder, unspecified- Used when the molecular pathology procedure is ordered to investigate unexplained metabolic disorders.
-
R82.90: Unspecified abnormal findings in urine- Indicates abnormal urine findings prompting further genetic or molecular investigation.
-
R94.39: Abnormal result of other cardiovascular function study- Used when abnormal cardiovascular study results lead to molecular testing for underlying genetic causes.
Related CPT Codes
81404: Molecular pathology procedure, Level 5 (eg, analysis of 2‑5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6‑10 exons, or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis)
81404 is related to 81403 as both are molecular pathology procedures, but 81404 covers more extensive analysis (2-5 exons or more complex mutation characterization). In clinical workflow, 81403 may be used for targeted analysis, while 81404 is used when broader or more complex genetic testing is required. These codes are alternatives depending on the scope of genetic analysis needed; they are not typically billed together for the same genetic region.
National Reimbursement Benchmarks
National mean rates for CPT code 81403 among commercial payers are highest with Blue Cross Blue Shield at $161.15, while the BUCA average stands at $144.51. Medicare rates are not available in the input, so only commercial benchmarks are presented. The mean rates for UnitedHealth Group and Cigna are $145.83 and $153.09, respectively, with Aetna at $126.64.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies across payers. Blue Cross Blue Shield shows the tightest range at $61.33, while Cigna exhibits the widest spread at $128.20. Aetna, UnitedHealth Group, and BUCA have intermediate ranges of $75.00, $89.00, and $83.67, respectively. This indicates that Cigna's rates are more variable nationally, while Blue Cross Blue Shield's rates are more consistent.
The table and chart below present the full breakdown of national benchmarks for CPT code 81403 by payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.